Se connecter

Bibliographies thématiques / Sch56002

Sommaire

Articles de revues
Thèses
Livres

Littérature scientifique sur le sujet « Sch56002 »

Auteur : Grafiati

Publié le 25 juillet 2024

Mis à jour le 31 juillet 2024

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Sch56002 ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Sch56002"

1

Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell. "In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans." Antimicrobial Agents and Chemotherapy 40, no. 8 (1996): 1910–13. http://dx.doi.org/10.1128/aac.40.8.1910.

Texte intégral

Résumé :

Multiple isolates of Cryptococcus neoformans were tested to compare the in vitro activity of a new triazole, SCH56592, with those of amphotericin B, fluconazole, and itraconazole, MICs of each drug were determined, and minimum fungicidal concentrations of SCH56592 and amphotericin B were measured. MICs of SCH56592 were lower than those of amphotericin B and fluconazole but not those of itraconazole. Minimum fungicidal concentrations of SCH56592 were lower than those of amphotericin B. SCH56592 in the presence of human serum produces an in vitro fungicidal effect for Cryptococcus neoformans. The data indicate that SCH56592 might exert fungicidal as well as inhibitory properties in vivo. On the basis of these results, SCH56592 was evaluated with a rabbit model of experimental cryptococcal meningitis; SCH56592 treatment was compared with treatment with fluconazole. Despite no detectable drug concentrations in the cerebrospinal fluid, the activity of SCH56592 against C. neoformans infection was equivalent to that of fluconazole. SCH56592 has potent in vitro activity against C. neoformans and compares favorably to treatment with fluconazole for a central nervous system infection. SCH56592 should be studied for use in humans with cryptococcal infections.

Styles APA, Harvard, Vancouver, ISO, etc.

2

Graybill, John R., Rosie Bocanegra, Laura K. Najvar, David Loebenberg, and Mike F. Luther. "Granulocyte Colony-Stimulating Factor and Azole Antifungal Therapy in Murine Aspergillosis: Role of Immune Suppression." Antimicrobial Agents and Chemotherapy 42, no. 10 (1998): 2467–73. http://dx.doi.org/10.1128/aac.42.10.2467.

Texte intégral

Résumé :

ABSTRACT Outbred ICR mice were immune suppressed either with hydrocortisone or with 5-fluorouracil and were infected intranasally withAspergillus fumigatus. Beginning 3 days before infection some groups of mice were given recombinant human granulocyte colony-stimulating factor (G-CSF), SCH56592 (an antifungal triazole), or both. Corticosteroid-pretreated mice responded to SCH56592 and had reduced counts in lung tissue and prolonged survival. In these mice, G-CSF strongly antagonized the antifungal activity of SCH56592. Animals treated with both agents developed large lung abscesses with polymorphonuclear leukocytes and large amounts ofAspergillus. In contrast, mice made neutropenic with 5-fluorouracil and then infected with A. fumigatusconidia benefited from either G-CSF or triazoles, and the effect of the combination was additive rather than antagonistic. Host predisposing factors contribute in different ways to the outcome of growth factor therapy in aspergillosis.

Styles APA, Harvard, Vancouver, ISO, etc.

3

Galgiani, J. N., and M. L. Lewis. "In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts." Antimicrobial Agents and Chemotherapy 41, no. 1 (1997): 180–83. http://dx.doi.org/10.1128/aac.41.1.180.

Texte intégral

Résumé :

We investigated the effects of various assay conditions on the activities of two antifungal drugs, SCH56592 and itraconazole, against seven species of fungi by the broth macrodilution testing procedure proposed by the National Committee for Clinical Laboratory Standards (NCCLS). For both drugs, which are insoluble in water, the concentration and type of solubilizing agent produced differences in drug activity. Starting inoculum size differences from 10(2) to 10(5) yeast cells per ml resulted in approximately a fourfold effect on the MIC of both drugs, but other significant differences were not observed with variations in synthetic medium composition, pH, buffering reagent, or incubation temperature. Under standardized conditions of reference method M27-T with 1% polyethylene glycol as the solubilizing agent, median MICs of SCH56592 and itraconazole of 60 and 125 mg/ml, respectively, were demonstrated for 110 strains (12 to 23 strains for each of seven species). Broth microdilution results were typically severalfold higher than broth macrodilution results. We conclude that the NCCLS standard reference method can be applied without modification to the testing of SCH56592 and itraconazole, but particular attention to solubilizing the agents is critical to obtaining consistent results.

Styles APA, Harvard, Vancouver, ISO, etc.

4

Espinel-Ingroff, Ana. "Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts." Journal of Clinical Microbiology 36, no. 10 (1998): 2950–56. http://dx.doi.org/10.1128/jcm.36.10.2950-2956.1998.

Texte intégral

Résumé :

The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 against 83 isolates of Acremonium strictum,Aspergillus flavus, Aspergillus fumigatus,Aspergillus terreus, Bipolaris spp.,Blastomyces dermatitidis, Cladophialophora bantiana, Fusarium oxysporum, Fusarium solani, Histoplasma capsulatum,Phialophora spp., Pseudallescheria boydii,Rhizopus arrhizus, Scedosporium prolificans, and Sporothrix schenckii were compared. The in vitro activities of these agents against 104 isolates of yeast pathogens ofCandida spp., Cryptococcus neoformans, andTrichosporon beigelii were also compared. MICs were determined by following a procedure under evaluation by the National Committee for Clinical Laboratory Standards (NCCLS) for broth microdilution testing of the filamentous fungi (visual MICs) and the NCCLS M27-A broth microdilution method for yeasts (both visual and turbidimetric MICs). The in vitro fungicidal activity of SCH56592 was superior (minimum fungicidal concentrations [MFCs], 0.25 to 4 μg/ml for 7 of 18 species tested) to those of MK-0991 and LY303366 (MFCs, 8 to >16 μg/ml for all species tested) for the molds tested, but the echinocandins had a broader spectrum of fungicidal activity (MFCs at which 90% of strains are inhibited [MFC90s], 0.5 to 4 μg/ml for 6 of 9 species tested) than SCH56592 (MFC90s, 0.25 to 8 μg/ml for 4 of 9 species tested) against most of the yeasts tested. Neither echinocandin had in vitro activity (MICs, >16 μg/ml) against C. neoformans and T. beigelii, while the SCH56592 MICs ranged from 0.12 to 1.0 μg/ml for these two species. The MICs of the three agents for the other species ranged from <0.03 to 4 μg/ml. These results suggest that these new agents have broad-spectrum activities in vitro; their effectiveness in the treatment of human mycoses is to be determined.

Styles APA, Harvard, Vancouver, ISO, etc.

5

Graybill, J. R., R. Bocanegra, L. K. Najvar, M. F. Luther, and D. Loebenberg. "SCH56592 treatment of murine invasive aspergillosis." Journal of Antimicrobial Chemotherapy 42, no. 4 (1998): 539–42. http://dx.doi.org/10.1093/jac/42.4.539.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Kirkpatrick, William R., Robert K. McAtee, Annette W. Fothergill, David Loebenberg, Michael G. Rinaldi, and Thomas F. Patterson. "Efficacy of SCH56592 in a Rabbit Model of Invasive Aspergillosis." Antimicrobial Agents and Chemotherapy 44, no. 3 (2000): 780–82. http://dx.doi.org/10.1128/aac.44.3.780-782.2000.

Texte intégral

Résumé :

ABSTRACT SCH56592 (SCH) was evaluated in an immunosuppressed rabbit model of invasive aspergillosis. SCH was more effective than similar doses of itraconazole and as effective as amphotericin B in the clearance ofAspergillus spp. from tissues. Compared with controls, SCH regimens reduced mortality, improved survival, and significantly reduced tissue colony counts.

Styles APA, Harvard, Vancouver, ISO, etc.

7

Hossain, Mohammad Ashraf, Shigefumi Maesaki, Kotaro Mitsutake, et al. "In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans." Journal of Antimicrobial Chemotherapy 44, no. 6 (1999): 827–29. http://dx.doi.org/10.1093/jac/44.6.827.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Espinel-Ingroff, A. "Germinated and Nongerminated Conidial Suspensions for Testing of Susceptibilities of Aspergillus spp. to Amphotericin B, Itraconazole, Posaconazole, Ravuconazole, and Voriconazole." Antimicrobial Agents and Chemotherapy 45, no. 2 (2001): 605–7. http://dx.doi.org/10.1128/aac.45.2.605-607.2001.

Texte intégral

Résumé :

ABSTRACT The effect of germinated and nongerminated conidia ofAspergillus spp. on the fungistatic (National Committee for Clinical Laboratory Standards document M38-P) and fungicidal activities (MICs and minimal fungicidal concentrations [MFCs] respectively) of amphotericin B, itraconazole, posaconazole (SCH56592), ravuconazole (BMS-207147), and voriconazole was evaluated. MFCs were the lowest drug dilutions that showed fewer than three colonies (99.9% killing). Overall, the MICs (0.12 to 4 μg/ml) and MFCs (0.5 to >8 μg/ml) of all of the agents tested with both inocula were the same or within 2 dilutions for the 72 isolates. Therefore, MICs and MFCs can be obtained with convenient and standardized nongerminated conidia.

Styles APA, Harvard, Vancouver, ISO, etc.

9

Manavathu, Elias K., Jessica Cutright, and Pranatharthi H. Chandrasekar. "Comparative Study of Susceptibilities of Germinated and Ungerminated Conidia of Aspergillus fumigatus to Various Antifungal Agents." Journal of Clinical Microbiology 37, no. 3 (1999): 858–61. http://dx.doi.org/10.1128/jcm.37.3.858-861.1999.

Texte intégral

Résumé :

Conidia are used as inocula for the in vitro susceptibility testing of Aspergillus fumigatus. Since the MIC is defined on the basis of visible mycelial growth, conidia should germinate and produce sporelings (germinated conidia) for monitoring of the growth inhibition and fungicidal activity of a drug. If a compound is capable of inhibiting germination of conidia while affecting or not affecting the growth of the organism, the MIC obtained will be the concentration of the drug required for the inhibition of conidial germination but not necessarily that required for inhibition of the growth of the organism. We investigated the susceptibility of germinated and ungerminated conidia to amphotericin B, itraconazole, voriconazole, and SCH56592. The MICs of various antifungal agents for germinated conidia were almost identical to those obtained for ungerminated conidia. In addition, both the germinated and ungerminated conidia were killed with almost equal efficiency by all of the compounds tested when exposed to the drugs for 24 h. These results suggest that either germinated or ungerminated conidia could be used as inocula for in vitro susceptibility studies of A. fumigatus with identical results.

Styles APA, Harvard, Vancouver, ISO, etc.

10

Yildiran, S. T., A. W. Fothergill, D. A. Sutton, and M. G. Rinaldi. "In vitrosusceptibilities of cerebrospinal fluid isolates ofCryptococcus neoformanscollected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592)." Mycoses 45, no. 9-10 (2002): 378–83. http://dx.doi.org/10.1046/j.1439-0507.2002.00765.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Thèses sur le sujet "Sch56002"

1

Walker, Edward Richard. "Studies towards the total synthesis of SCH56036." Thesis, Imperial College London, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415665.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Livres sur le sujet "Sch56002"

1

Oogenesis. Springer London, Limited, 2016.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Oogenesis. Springer London, Limited, 2012.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Otruba, Kathy. SCH5620 Desktop Embedded Controller with Fan Control, Hardware Monitoring and PECI - Product Brief. Microchip Technology Incorporated, 2014.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!